Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3389 - Long lasting responses to adoptive T-cell therapy in relapsed EBV-related nasopharyngeal carcinoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Simona Secondino

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

S. Secondino1, P. Bossi2, A. Gurrado3, S. Basso3, I. Imarisio1, A. Pagani1, M. Zecca4, I. Pisani3, J. Bagnarino3, M. Casanova5, C. Bergamini2, C. Perotti6, L.F. Licitra2, P. Comoli3, P. Pedrazzoli1

Author affiliations

  • 1 Oncology Departement, Fondazione IRCCS Policlinico San Matteo, 27100 - Pavia/IT
  • 2 Head And Neck Medical Oncology Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Cell Factory, Fondazione IRCCS Policlinico San Matteo, 27100 - Pavia/IT
  • 4 Pediatric Hematology Oncology Department, Fondazione IRCCS Policlinico San Matteo, 27100 - Pavia/IT
  • 5 Pediatric Oncology Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milano/IT
  • 6 Immunohaematology And Transfusion Service, Fondazione IRCCS Policlinico San Matteo, 27100 - Pavia/IT
More

Resources

Abstract 3389

Background

Epstein-Barr virus (EBV)-related Nasopharyngeal carcinoma (NPC) is a highly chemo-radiosensitive cancer. However, when relapsing without surgical or reirradiation options, NPC carries a dismal prognosis; survival >2 years being reported in 7-14% metastatic pts (1,2). We have previously achieved disease control using autologous EBV-specific cytotoxic T lymphocytes (CTL) in refractory/relapsed pts following conventional treatments (3). The aim of the present study was to evaluate outcomes in pts receiving T-cell therapy after first line chemotherapy (CT) for recurrent disease.

Methods

Sixteen patients (13 males, median age 41 yrs) with metastatic (n = 12; 7/12 with visceral metastasis, and 5/12 with bone and nodes lesions) or locally recurrent (n = 4) NPC received 2 administrations of EBV-specific CTL at a total cell dose/infusion of 1.5-3 x 108, following completion of first line CT. The best response after first-line CT had been progressive disease (PD) in 4 pts, stable disease (SD) in 3, partial response (PR) in 5 and complete response (CR) in 4.

Results

No severe adverse events were recorded, following CTL therapy. Among patients in CR after first-line CT, 3 remain in CR at 58, 76 and 77+ months, while one patient relapsed, but attained a long-lasting CR after treatment with 2nd-line CT. In the 12 patients treated with persistent disease (PR, SD, PD), the best response observed after CTL therapy, in some cases (3/12) associated with 1subsequent line of CT or radiotherapy, was PD in 8 patients, and CR (range 39-78+ months) in 4. At a median follow-up of 64 months, 8/16 patients are alive with no evidence of disease. Among the factors associated with positive outcome are response to first-line CT, and metastatic disease with limited tumor burden.

Conclusions

EBV-specific CTL therapy administered following first line CT for recurrent NPC, is safe and associated with remarkable clinical benefit in some patients, including long-lasting CR.

Clinical trial identification

Legal entity responsible for the study

Fondazione IRCCS Policlinico San Matteo Pavia.

Funding

Fondazione IRCCS Policlinico San Matteo, Ricerca Corrente RCR.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.